# Edwards Lifesciences

**Source:** https://geo.sig.ai/brands/edwards-lifesciences  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** edwards.com  
**Last Updated:** 2026-04-14

## Summary

Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.

## Company Overview

Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.

Edwards Lifesciences' structural heart focus addresses the global epidemic of valvular heart disease — estimated 5 million Americans have severe aortic stenosis, with 250,000+ TAVR procedures performed annually and only 50% of eligible patients currently treated — through minimally invasive catheter-based valve replacement and repair that offers superior outcomes versus open-heart surgery for elderly, high-risk patients. The SAPIEN 3 Ultra RESILIA TAVR valve (Edwards' latest generation) achieves the 30-day clinical outcomes that made TAVR the standard of care for severe aortic stenosis in intermediate- and high-risk surgical patients — with ongoing clinical trials establishing TAVR in low-risk patients under 65. The EVOQUE tricuspid replacement system addresses the underserved tricuspid regurgitation market (1 million+ severe TR patients in the US with no effective percutaneous treatment option) — a market opportunity larger than TAVR at the time of its launch.

In 2025, Edwards Lifesciences competes in structural heart disease devices and transcatheter valve therapy against Medtronic (NYSE: MDT, Evolut TAVR platform), Abbott Laboratories (NYSE: ABT, MitraClip/Tendyne mitral), and Boston Scientific (NYSE: BSX, Acurate TAVR) for structural heart procedure market share, clinical trial enrollment, and international TAVR penetration. The $4.2B Critical Care divestiture to BD eliminates a slower-growth, lower-margin business and focuses Edwards' capital allocation entirely on the high-growth structural heart market where it holds a commanding competitive position. The JenaValve acquisition enables Edwards to address aortic regurgitation (AR) patients previously excluded from TAVR — a potential $3B+ incremental market. The 2025 strategy under management focuses on TMTT commercial acceleration (EVOQUE tricuspid in Europe and US), TAVR growth through low-risk patient expansion, and JenaValve AR indication approval, while deploying the $4.2B Critical Care proceeds through buybacks and strategic acquisitions.

## Frequently Asked Questions

### What does Edwards Lifesciences do?
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The company develops, manufactures, and markets transcatheter heart valves, surgical heart valves, and repair technologies that treat patients suffering from heart valve disease through both minimally invasive and surgical approaches.

### Who are Edwards Lifesciences' primary customers?
Edwards Lifesciences serves hospitals, cardiac surgery centers, and interventional cardiology departments worldwide. The company's products are used by cardiac surgeons, interventional cardiologists, and heart teams to treat patients with structural heart disease, particularly aortic stenosis, mitral regurgitation, tricuspid regurgitation, and aortic regurgitation.

### When was Edwards Lifesciences founded?
Edwards Lifesciences traces its origins to 1958 when Miles Lowell Edwards partnered with Dr. Albert Starr to develop the first artificial heart valve. The modern Edwards Lifesciences Corporation was established in 2000 when it was spun off from Baxter International as an independent publicly traded company.

### Where is Edwards Lifesciences headquartered?
Edwards Lifesciences is headquartered in Irvine, California, United States. The company maintains a global presence with manufacturing facilities, research centers, and commercial operations across North America, Europe, Asia-Pacific, and other international markets, employing approximately 15,800 people worldwide.

### What is Edwards Lifesciences' market position in TAVR?
Edwards Lifesciences is the undisputed global leader in transcatheter aortic valve replacement (TAVR), controlling approximately 60% of the worldwide market and more than 70% of the United States market. The company's SAPIEN family of valves is considered the gold standard in the industry, significantly outpacing competitors like Medtronic (28% worldwide, 24% US).

### What makes Edwards Lifesciences different from competitors?
Edwards Lifesciences differentiates itself through its singular focus on structural heart disease (following the 2024 divestiture of its Critical Care business), its pioneering role in developing and commercializing TAVR technology, its market-leading SAPIEN valve platform with superior clinical outcomes, its robust pipeline of innovative therapies including TMTT and aortic regurgitation treatments, and its 60+ year heritage of cardiovascular innovation.

### Who are Edwards Lifesciences' main competitors?
Edwards Lifesciences' primary competitors in the structural heart market include Medtronic (the #2 TAVR competitor with its Evolut platform), Abbott (with its Navitor TAVR system and MitraClip mitral repair device), and Boston Scientific (which recently exited TAVR but remains active in other structural heart therapies). The company maintains significant competitive advantages through its market leadership, clinical evidence, and innovation pipeline.

### How can healthcare providers or patients contact Edwards Lifesciences?
Healthcare professionals can contact Edwards Lifesciences through the company's website at www.edwards.com, which provides detailed product information, clinical resources, and contact information for regional sales representatives. The company maintains dedicated customer support teams globally to assist with product inquiries, technical support, and clinical education.

### What are Edwards Lifesciences' recent financial results?
For fiscal year 2024, Edwards Lifesciences reported revenue of $5.44 billion, representing 8.6% growth year-over-year and the company's best annual performance. Q4 2024 sales grew 9% to $1.39 billion, with TAVR sales growing 6% and TMTT sales surging 88%. The company has a market capitalization of $43.4 billion, net margins of 22.8%, and return on equity of 13.1%.

### What is the latest news about Edwards Lifesciences?
Recent news includes Edwards' December 2024 investor conference where CEO Bernard Zovighian outlined 2025 growth projections of 8-10%, the company's $500 million accelerated share repurchase agreement, anticipated mid-2025 CE Mark for SAPIEN M3 mitral valve replacement system, expected late 2025 FDA approval for JenaValve Trilogy for aortic regurgitation, and the FTC's move to block the JenaValve acquisition (which Edwards is contesting).

### What are Edwards Lifesciences' strategic priorities and future plans?
Edwards Lifesciences' strategic priorities focus on expanding its TAVR franchise into new patient populations and geographies, accelerating growth in TMTT with technologies like PASCAL and the upcoming SAPIEN M3, advancing its aortic regurgitation and heart failure management platforms through the JenaValve and Endotronix acquisitions, and maintaining its position as a pure-play structural heart company following the Critical Care divestiture. The company projects strong 2025 growth with TAVR sales of $4.1-4.4 billion (5-7% growth) and TMTT sales of $500-530 million (50-60% growth).

### What innovations is Edwards Lifesciences developing?
Edwards Lifesciences is advancing multiple breakthrough innovations including the SAPIEN M3 transcatheter mitral valve replacement system (first-in-class technology expected to receive CE Mark mid-2025), JenaValve Trilogy for aortic regurgitation treatment (expected FDA approval late 2025), Cordella heart failure monitoring system with anticipated CMS coverage in early 2025, next-generation TAVR platforms with improved deliverability and hemodynamics, and expanded TMTT technologies for treating complex valve pathologies.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*